The expiration of Novo Nordisks patent in 2026 and increased competition from Indian pharmaceutical players will lower prices
Sequence-structure relationships in polysaccharide co-polymerase (PCP) proteins
Eligibility is based on BMI of 35 or more alone, or 27 or more plus other clinical criteria
Your provider will never increase your dose faster than your body is ready for
Seek medical advice if fatigue: Persists beyond several months without improvement, despite adequate nutrition and hydration Worsens progressively or becomes debilitating, significantly impairing daily activities or work capacity Is accompanied by severe or persistent gastrointestinal symptoms (intractable nausea, vomiting, diarrhoea, abdominal pain) Occurs alongside signs of dehydration (dark urine, dizziness, reduced urine output, dry mouth) Is associated with symptoms of hypoglycaemia (tremor, sweating, confusion, palpitations), particularly in patients taking concurrent insulin or sulphonylureas Urgent medical attention is required if patients experience: Severe abdominal pain , especially if radiating to the back, which may indicate pancreatitisa rare but serious adverse effect of GLP-1 medications
Current evidence does not show a consistent effect of Lcarnitine on INR, but published data are sparse
